Log in

Relevant bibliographies by topics / Stage of cancer / Journal articles

To see the other types of publications on this topic, follow the link: Stage of cancer.

Journal articles on the topic 'Stage of cancer'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Stage of cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hubbell, Earl, and Christina Clarke. "Abstract 2239: Detecting cancer when it can be cured: The potential for cure across all stageable cancers." Cancer Research 82, no. 12_Supplement (2022): 2239. http://dx.doi.org/10.1158/1538-7445.am2022-2239.

Full text

Abstract:

Abstract Introduction: Early detection of cancer may reduce cancer mortality by providing access to treatments with the potential to cure cancer at early stages. A mixture cure model divides cancer cases into two populations: one where cancer is likely to severely impact mortality (not-cured) and one where long-term survival with low risk is possible (cured). Previous work on such models has concentrated on estimating cure for either many cancer types without regard to stage (public health arena), or single cancers by stage at diagnosis (screening arena). A gap in the current literature is an

APA, Harvard, Vancouver, ISO, and other styles

2

Chhatwal, Jagpreet, Andrew ElHabr, Christopher Tyson, et al. "Correlation of unobserved incidence of cancer in earlier stages with the observed incidence." Journal of Clinical Oncology 41, no. 16_suppl (2023): 10634. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10634.

Full text

Abstract:

10634 Background: Population-level cancer registries report observed (screening or clinically detected) incident cancer cases. However, the underlying true cancer incidence may be higher than observed. We estimate the unobserved cancer incidence by stage for eight different cancers. Methods: Using the CDC’s National Program of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) combined incidence databases, we first estimated observed incidence rates by cancer type and stage. Newly observed cancers in later stages must have existed at

APA, Harvard, Vancouver, ISO, and other styles

3

Lazarev, A. F., V. D. Petrova, T. V. Sinkina, and S. A. Terekhova. "New approaches to cancer prevention—preventive medical examination of patients from the high-risk pre-cancer registry." Journal of Clinical Oncology 25, no. 18_suppl (2007): 1546. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1546.

Full text

Abstract:

1546 Background: Such methods of cancer prevention as checkup in rooms for seeing patients’ examination, mass prophylactic examination, screening tests, which are currently in use in Russian Federation, are able to provide detectability of malignancies no more than 0.1%. The research objective was to increase the effectiveness of cancer detection by means of forming of the high-risk pre-cancer registry. Methods: With the help of multivariative analysis the patients with the high risk of malignancies (80–100%) were selected for the high-risk pre-cancer registry. It included patients with obliga

APA, Harvard, Vancouver, ISO, and other styles

4

Zhou, Yaning, Yijun Guo, Qing Cui, et al. "Application of Thromboelastography to Predict Lung Cancer Stage." Technology in Cancer Research & Treatment 19 (January 1, 2020): 153303382095235. http://dx.doi.org/10.1177/1533033820952351.

Full text

Abstract:

Objective: Lung cancer is often associated with hypercoagulability. Thromboelastography provides integrated information on clot formation in whole blood. This study explored the possible relationship between thromboelastography and lung cancer. Methods: Lung cancer was staged according to the Tumor, Node, and Metastasis (TNM) classification system. Thromboelastography parameters in different stages of disease were compared. The value of thromboelastography for stage prediction was determined by area under the receiver operating characteristic curve analysis. Results: A total of 182 patients di

APA, Harvard, Vancouver, ISO, and other styles

5

Anakwenze, Chidinma, Rohini Bhatia, William Rate, et al. "Factors Related to Advanced Stage of Cancer Presentation in Botswana." Journal of Global Oncology, no. 4 (December 2018): 1–9. http://dx.doi.org/10.1200/jgo.18.00129.

Full text

Abstract:

Purpose Botswana, a country with a high prevalence of HIV, has an increasing incidence of cancer-related mortality in the post–antiretroviral therapy era. Despite universal access to free health care, the majority of Botswana patients with cancer present at advanced stages. This study was designed to explore the factors related to advanced-stage cancer presentation in Botswana. Methods Patients attending an oncology clinic between December 2015 and January 2017 at Princess Marina Hospital in Gaborone, Botswana, completed a questionnaire on sociodemographic and clinical factors as well as cance

APA, Harvard, Vancouver, ISO, and other styles

6

Guo, Wei, Yunlong Hu, Wei Wang, et al. "Assessment of plasma cell-free DNA fragmentation for multi-cancer early detection: An independent clinical validation study." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15037-e15037. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15037.

Full text

Abstract:

e15037 Background: Cell-free DNA (cfDNA) in the circulation has gained significant attention due to its potential applications for non-invasive early cancer detection. Fragmentomics of cfDNA is emerging as a promising field of biomarker research, exhibiting the capability to sensitively detect multiple cancer types. In previous retrospective research, we developed an approach called PatternWGS for comprehensive analysis of cfDNA fragmentation patterns and presented a multi-cancer detection model. In this study, we aim to evaluate the performance of PatternWGS in an independent validation cohor

APA, Harvard, Vancouver, ISO, and other styles

7

Young, Jessica S., Kazuaki Takabe, Mariko Asaoka, and Stephen B. Edge. "Comparing the American Joint Committee on Cancer (AJCC) breast cancer staging eighth versus seventh edition and breast cancer biology in large databases." Journal of Clinical Oncology 37, no. 15_suppl (2019): e12077-e12077. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e12077.

Full text

Abstract:

e12077 Background: The AJCC 8th edition Breast Cancer Staging system includes biomarkers (estrogen receptor, progesterone receptor, Her2), grade and a genomic assay, to better reflect outcomes, compared to the 7th edition. We used databases with anatomic, biomarker and genomic information to determine if the 8th edition reflects biology better than the 7th edition. Methods: 696 breast cancer patients in The Cancer Genome Atlas (TCGA) and Text Information Extraction System (TIES) were staged both with 7th and 8th edition. Results: From the 7th to 8th editions, 66% of stage 2 patients migrated (

APA, Harvard, Vancouver, ISO, and other styles

8

Long, R., A. Woods, C. Biondi, et al. "Collection and Reporting of National Cancer Stage at Diagnosis Data in Australia (STaR Project)." Journal of Global Oncology 4, Supplement 2 (2018): 67s. http://dx.doi.org/10.1200/jgo.18.61300.

Full text

Abstract:

Background: Stage at diagnosis is an important prognostic factor for cancer, providing contextual information for interpreting population health indicators such as mortality from cancer and cancer survival. Australian population-based cancer registries (PBCRs) routinely collect information on cancer incidence and mortality. The need for high quality, comprehensive national data on stage at diagnosis to supplement these data are widely recognized in Australia. The collection and dissemination of quality national stage data will enhance the: • ability to better monitor cancer outcomes, inform ca

APA, Harvard, Vancouver, ISO, and other styles

9

Olson, David C., Khaled Mohamed Abou El-Ezz, and Peter T. Silberstein. "Choice of therapy and time to first treatment for patients with colon cancer: A National Cancer Database analysis." Journal of Clinical Oncology 31, no. 15_suppl (2013): e14642-e14642. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14642.

Full text

Abstract:

e14642 Background: Insurance status has been shown to affect adherence to guidelines in the treatment of colon cancer1. This study aims to investigate trends in management of colon cancer and time to first treatment in patients with various insurance types using the National Cancer Database (NCDB). Methods: Treatment data for 845,121 patients and time to first treatment data for 497,993 patients diagnosed with colon cancer between 2000 and 2010 were identified using the NCDB. Reported utilization of treatment and time to first treatment were analyzed by insurance status. Results: Among all sta

APA, Harvard, Vancouver, ISO, and other styles

10

Kida, Kumiko, Kenneth R. Hess, Bora Lim, et al. "Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer." Cancers 12, no. 11 (2020): 3105. http://dx.doi.org/10.3390/cancers12113105.

Full text

Abstract:

The AJCC updated its breast cancer staging system to incorporate biological factors in the “prognostic stage”. We undertook this study to validate the prognostic and anatomic stages for inflammatory breast cancer (IBC). We established two cohorts of IBC diagnosed without distant metastasis: (1) patients treated at The University of Texas MD Anderson Cancer Center between 1991 and 2017 (MDA cohort) and (2) patients registered in the national Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 (SEER cohort). For prognostic staging, estrogen receptor (ER)+/progestero

APA, Harvard, Vancouver, ISO, and other styles

11

Saraste, D., A. Martling, PJ Nilsson, J. Blom, S. Törnberg, and M. Janson. "Screening vs. non-screening detected colorectal cancer: Differences in pre-therapeutic work up and treatment." Journal of Medical Screening 24, no. 2 (2016): 69–74. http://dx.doi.org/10.1177/0969141316656216.

Full text

Abstract:

Objectives To compare preoperative staging, multidisciplinary team-assessment, and treatment in patients with screening detected and non-screening detected colorectal cancer. Methods Data on patient and tumour characteristics, staging, multidisciplinary team-assessment and treatment in patients with screening and non-screening detected colorectal cancer from 2008 to 2012 were collected from the Stockholm–Gotland screening register and the Swedish Colorectal Cancer Registry. Results The screening group had a higher proportion of stage I disease (41 vs. 15%; p < 0.001), a more complete stagin

APA, Harvard, Vancouver, ISO, and other styles

12

Ciatto, Stefano, Paolo Pacini, Patrizia Bravetti, et al. "Staging Breast Cancer - Screening for Occult Metastases." Tumori Journal 71, no. 4 (1985): 339–44. http://dx.doi.org/10.1177/030089168507100404.

Full text

Abstract:

The authors report on 1,017 consecutive breast cancer cases without symptomatic metastases staged by means of chest X-ray (CXR), skeletal survey (BXR) and bone scintigraphy (BS). Occult metastases (DM) detection rate was 0.88 %: 0.29 % for lung and 0.59 % for bone DM. The detection rate was correlated with clinical stage: 0.36 % for stage I, 0.20 % for stage II, 0.26 % for stages I and II, and 2.77 % for stage III cases. The sensitivity based on DM cases prevalent or surfacing within 6 months of follow-up was 0.30 for CXR, 0.22 for BXR and 0.55 for BS; specificity was 0.99, 0.98 and 0.90, resp

APA, Harvard, Vancouver, ISO, and other styles

13

Fedorenko, Catherine R., Karma L. Kreizenbeck, Li Li, Laura Elizabeth Panattoni, Veena Shankaran, and Scott David Ramsey. "Stage at cancer diagnosis during the COVID-19 pandemic in western Washington state." Journal of Clinical Oncology 39, no. 28_suppl (2021): 145. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.145.

Full text

Abstract:

145 Background: The COVID-19 pandemic disrupted medical care, including routine cancer screening for breast, colorectal, lung and cervical cancers. We aimed to investigate the impact of the pandemic on stage at diagnosis for cancer patients. Methods: Using data from the Washington State SEER records we compared AJCC stage for patients diagnosed with cancer in 2017-2019 to 2020 for two time periods, March to June (initial pandemic months) and July to December (later pandemic months). Patients were included if they were age 18+, diagnosed with a solid tumor, and not diagnosed at autopsy. Results

APA, Harvard, Vancouver, ISO, and other styles

14

Chhatwal, Jagpreet, Jade Xiao, Selin Merdan, et al. "Effect of multi-cancer early detection screening on late-stage cancers: A modeling study." Journal of Clinical Oncology 42, no. 16_suppl (2024): 11076. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.11076.

Full text

Abstract:

11076 Background: Emerging blood-based multi-cancer early detection (MCED) tests can revolutionize early cancer detection. We evaluated the potential impact of MCED screening in reducing risk of late-stage diagnosis of 12 specific cancers which represent 70% of all cancer incidence in the US. Methods: We developed Simulation Model for MCED (SiMCED), a microsimulation model of 12 solid tumor cancer types: breast, colorectal, endometrial, esophageal, gastric, kidney, liver, lung, ovarian, pancreatic, prostate, and urinary bladder. Transitions between cancer stages (I-IV) were driven by cancer ty

APA, Harvard, Vancouver, ISO, and other styles

15

Wu, Wendy, Jian Bai, Siqi Wang, et al. "Evaluation of cost-effective multiple cancer early detection with extremely low coverage whole genome sequencing from plasma." Journal of Clinical Oncology 42, no. 16_suppl (2024): 10538. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.10538.

Full text

Abstract:

10538 Background: Cancer continues to be a significant global health concern, with approximately 19.3 million new cases diagnosed and 10.0 million cancer-related deaths reported in 2020. Multi-cancer early detection (MCED) test using the peripheral blood offers a great opportunity to improve the current cancer screening tests with better performance and benefit-to-harm balance. Methods: Here we introduce a novel MCED test called HIFI-PROF, which utilizes extremely low pass whole-genome sequencing (median coverage of 0.6X) to create a multi-dimensional fragmentation signatures model through mac

APA, Harvard, Vancouver, ISO, and other styles

16

Weiss, Jennifer M., Patrick R. Pfau, Erin S. O'Connor, et al. "Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare Data." Journal of Clinical Oncology 29, no. 33 (2011): 4401–9. http://dx.doi.org/10.1200/jco.2011.36.4414.

Full text

Abstract:

Purpose Recent studies have reported increased mortality for right-sided colon cancers but had limited adjustment for patient characteristics and conflicting results by stage. We examined the relationship between colon cancer location (right- v left-side) and 5-year mortality by stage. Patients and Methods We identified Medicare beneficiaries from 1992 to 2005 with American Joint Commission on Cancer stages I to III primary adenocarcinoma of the colon who underwent surgery for curative intent through Surveillance, Epidemiology, and End Results (SEER) –Medicare data. Adjusted hazard ratios (HRs

APA, Harvard, Vancouver, ISO, and other styles

17

Valkova, L. E., A. A. Dyachenko, V. M. Merabishvili та ін. "Impact of the СOVID-19 pandemic on cancer incidence in patients undergoing cancer screening during annual health checkup (population-based study)". Siberian journal of oncology 21, № 6 (2022): 7–16. http://dx.doi.org/10.21294/1814-4861-2022-21-6-7-16.

Full text

Abstract:

Background. During the COVID-19 pandemic, annual adult check-ups have been postponed, resulting in cancer screening disruption.The aim of the study was to evaluate changes in the incidence and stage distribution of malignancies included in the screening program during the COVID-19 pandemic using the Arkhangelsk Regional Cancer Registry (ARRC).Material and Methods. We assessed the changes of the incidence rates and stage distribution for the colon, rectum, lung, breast, cervix, uterine body, ovary, prostate and kidney cancers over the periods 2018–19 and 2020–21. Results. A total of 12354 cases

APA, Harvard, Vancouver, ISO, and other styles

18

Gerald, Thomas, Vitaly Margulis, Xiaosong Meng, et al. "Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients." Journal of Clinical Oncology 40, no. 6_suppl (2022): 525. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.525.

Full text

Abstract:

525 Background: Recent targeted therapies for advanced and metastatic urothelial cancer have generated enthusiasm, but the actionable genomic landscape of early-stage disease remains largely unknown. Here, we used real-world evidence to investigate differences between somatic and germline mutations in localized, early-stage urothelial cancers and advanced urothelial cancers. Methods: We retrospectively analyzed de-identified NGS data from 1,146 bladder cancer patients (stages I-IV) with formalin-fixed, paraffin-embedded tumor biopsies sequenced using the Tempus|xT solid tumor assay (DNA-seq of

APA, Harvard, Vancouver, ISO, and other styles

19

Pollard, Morris, and Mark A. Suckow. "Hormone-Refractory Prostate Cancer in the Lobund-Wistar Rat." Experimental Biology and Medicine 230, no. 8 (2005): 520–26. http://dx.doi.org/10.1177/153537020523000802.

Full text

Abstract:

Research on cancer prevention and therapy must focus on the refractory disease, the fatal end-stage of cancer that develops in patients with organ-related solid tumors. Refractory cancers develop spontaneously in advanced-stage tumors or in relapsed cases after failed therapy. Because neither prevention nor therapy is currently feasible, refractory cancer is a major impediment to survival. There is a great need for an animal model of prostate cancer (PC), one that develops cancer from initial premalignant to the terminal refractory stages. We describe here a model of hormone-refractory prostat

APA, Harvard, Vancouver, ISO, and other styles

20

Jafri, Syed Hasan Raza, Julie Haewon Rowe, Jessica Trevino Jones, et al. "A novel staging system for cancer cachexia." Journal of Clinical Oncology 43, no. 16_suppl (2025): 12073. https://doi.org/10.1200/jco.2025.43.16_suppl.12073.

Full text

Abstract:

12073 Background: Cancer cachexia affects a large percentage of advanced cancer patients. It’s defined by a consensus definition of unintentional >5% body weight loss over six months. There is no standard way of assessing severity of cancer cachexia. We developed a novel cancer cachexia staging system based on routine clinical parameters. Methods: In a prospective case control study of newly diagnosed cancer patients to identify biomarkers of cancer cachexia, cases were patients with stage III/IV cancer and >5% body weight loss and serum albumin of <3.5g/dl. Controls were patients wit

APA, Harvard, Vancouver, ISO, and other styles

21

Zhou, Jade, Shelly Kane, Celia Ramsey, et al. "The impact of the COVID-19 pandemic on stage at diagnosis of breast and colorectal cancers." Journal of Clinical Oncology 39, no. 15_suppl (2021): 6501. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.6501.

Full text

Abstract:

6501 Background: Effective cancer screening leads to a substantial increase in the detection of earlier stages of cancer, while decreasing the incidence of later stage cancer diagnoses. Timely screening programs are critical in reducing cancer-related mortality in both breast and colorectal cancer by detecting tumors at an early, curable stage. The COVID-19 pandemic resulted in the postponement or cancellation of many screening procedures, due to both patient fears of exposures within the healthcare system as well as the cancellation of some elective procedures. We sought to identify how the C

APA, Harvard, Vancouver, ISO, and other styles

22

Chang, Ellen T., Christina A. Clarke, Graham A. Colditz, Scarlett L. Gomez, Allison W. Kurian, and Earl A. Hubbell. "Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer." Journal of Clinical Oncology 41, no. 16_suppl (2023): 10535. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10535.

Full text

Abstract:

10535 Background: Lead-time bias occurs when cancer is detected earlier in time, but with no change in lifespan. Cause of death is not susceptible to lead-time bias; therefore, stratifying cause of death by cancer stage informs the potential for lead-time bias in early detection across cancer types. Methods: Using recent data from 17 US Surveillance, Epidemiology, and End Results (SEER) cancer registries for 1 152 610 first incident primary cancers among patients aged 50–84 years at diagnosis in 2006–2010, we evaluated proportional causes of death by cancer type and uniformly classified stage

APA, Harvard, Vancouver, ISO, and other styles

23

Suwanvecho, Suthida, Harit Suwanrusme, Surasit Issarachai, et al. "Concordance between a clinical decision-support system and treatments selected by clinicians as a function of cancer type or stage." Journal of Global Oncology 5, suppl (2019): 95. http://dx.doi.org/10.1200/jgo.2019.5.suppl.95.

Full text

Abstract:

95 Background: Watson for Oncology (WFO) is an artificial intelligence (AI) based clinical decision-support tool trained by Memorial Sloan Kettering. This retrospective observational study of breast, lung, colon and rectal cancer examined the concordance of treatment options provided by WFO to treatments selected by clinicians at Bumrungrad International Hospital (BIH) as a function of stage or cancer type. Methods: Concordance between WFO treatment options and treatments selected by BIH clinicians (WFO-BIH concordance) was defined as identical or equally acceptable treatments, as determined b

APA, Harvard, Vancouver, ISO, and other styles

24

Kaushal, Arjita. "Breast Cancer in Women, Signs and Treatment Approaches." NewBioWorld 2, no. 1 (2020): 25–27. http://dx.doi.org/10.52228/nbw-jaab.2020-2-1-5.

Full text

Abstract:

Cancer starts when cells start to grow out of control. Here we talk about breast cancer which starts in the breast hence the name. It is the second most common cause of death of cancer among women all over the world. Occur mostly in women but also in men. 5-10% of breast cancers are directly linked to generational mutations, parts of the breast that start breast cancer, such as lobules, ducts, and nipples. There are many types of treatment they have their pros and cons. Some tests that examine the breasts are used to diagnose breast cancer, like physical examination and health history, clinica

APA, Harvard, Vancouver, ISO, and other styles

25

Mori, Mio, Tomoyuki Fujioka, Kazunori Kubota, et al. "Relationship between Prognostic Stage in Breast Cancer and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography." Journal of Clinical Medicine 10, no. 14 (2021): 3173. http://dx.doi.org/10.3390/jcm10143173.

Full text

Abstract:

This retrospective study examined the relationship between the standardized uptake value max (SUVmax) of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and the prognostic stage of breast cancer. We examined 358 breast cancers in 334 patients who underwent 18F-FDG PET/CT for initial staging between January 2016 and December 2019. We extracted data including SUVmax of 18F-FDG PET and pathological biomarkers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and nuclear grade. Anatomical

APA, Harvard, Vancouver, ISO, and other styles

26

Palomba, Stefano, Fabio Ghezzi, Angela Falbo, et al. "Laparoscopic Versus Abdominal Approach to Endometrial Cancer: A 10-Year Retrospective Multicenter Analysis." International Journal of Gynecologic Cancer 22, no. 3 (2012): 425–33. http://dx.doi.org/10.1097/igc.0b013e318244248c.

Full text

Abstract:

ObjectiveThe objective of this study was to give a reality-based picture of the use of laparoscopic surgery for staging endometrial cancer patients out of the experimental setting.MethodsConsecutive data of patients with endometrial cancer who underwent laparoscopic or abdominal surgical staging in 6 Italian centers were recorded. Baseline patients and tumors characteristics, surgery performed, and safety data were collected and analyzed.ResultsA total of 1012 subjects (403 and 609 treated by laparoscopy and laparotomy, respectively) who received surgical stadiation for endometrial cancer were

APA, Harvard, Vancouver, ISO, and other styles

27

Broder, Michael S., Sikander Ailawadhi, Himisha Beltran, et al. "Estimates of stage-specific preclinical sojourn time across 21 cancer types." Journal of Clinical Oncology 39, no. 15_suppl (2021): e18584-e18584. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18584.

Full text

Abstract:

e18584 Background: Cancer progression rates following diagnosis are readily measured. However, the progression rate of cancer during the preclinical sojourn time is generally unobserved. Understanding the duration of preclinical stages (“dwell time”) would allow clinicians to better identify appropriate screening intervals for cancer. We therefore elicited estimates of progression rate during the preclinical sojourn time for a wide variety of malignancies from a panel of clinical experts. Methods: We used a validated consensus methodology (RAND/UCLA modified Delphi panel method) to elicit per-

APA, Harvard, Vancouver, ISO, and other styles

28

Ginsburg, O. M., H. D. Fischer, B. R. Shah, et al. "A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario." Current Oncology 22, no. 2 (2015): 97. http://dx.doi.org/10.3747/co.22.2359.

Full text

Abstract:

BackgroundBreast cancer stage at diagnosis is an important predictor of survival. Our goal was to compare breast cancer stage at diagnosis (by American Joint Committee on Cancer criteria) in Chinese and South Asian women with stage at diagnosis in the remaining general population in Ontario.MethodsWe used the Ontario population-based cancer registry to identify all women diagnosed with breast cancer during 2005–2010, and we applied a validated surname algorithm to identify South Asian and Chinese women. We used logistic regression to compare, for Chinese or South Asian women and for the remain

APA, Harvard, Vancouver, ISO, and other styles

29

Sato, Akira, Eiji Aramaki, Yumiko Shimamoto, Shiro Tanaka, and Koji Kawakami. "Blog Posting After Lung Cancer Notification: Content Analysis of Blogs Written by Patients or Their Families." JMIR Cancer 1, no. 1 (2015): e5. http://dx.doi.org/10.2196/cancer.3883.

Full text

Abstract:

Background The advent and spread of the Internet has changed the way societies communicate. A portion of information on the Internet may constitute an important source of information concerning the experiences and thoughts of patients and their families. Patients and their families use blogs to obtain updated information, search for alternative treatments, facilitate communication with other patients, and receive emotional support. However, much of this information has yet to be actively utilized by health care professionals. Objective We analyzed health-related information in blogs from Japan

APA, Harvard, Vancouver, ISO, and other styles

30

LING, EDUARD, AMIT RINGEL, INA SIGAL-BATIKOFF, et al. "Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts." Anticancer Research 36, no. 9 (2016): 4503–8. http://dx.doi.org/10.21873/anticanres.10996.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Nomura, Motoo, Tetsuya Abe, Azusa Komori, et al. "Implications for the American Joint Committee on Cancer staging systems on esophageal squamous cell cancer patients receiving multimodality therapy." Journal of Clinical Oncology 32, no. 3_suppl (2014): 123. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.123.

Full text

Abstract:

123 Background: The 7th edition of the American Joint Committee on Cancer (AJCC) staging system is based on pathologic data from esophageal cancers treated by surgery alone. The objective of this study was to evaluate the prognostic impact of the pretreatment clinical stage (cTNM) and posttreatment pathologic stage (ypTNM) on esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery (NAC-S). Methods: Information on 245 consecutive esophageal squamous cell carcinoma patients undergoing NAC-S was reviewed. Data collected included demographics, cTNM, ypTNM, and survival.

APA, Harvard, Vancouver, ISO, and other styles

32

Pokharel, Gyanendra, Qinggang Wang, Momtafin Khan, Paula J. Robson, Lorraine Shack, and Karen A. Kopciuk. "Stage Shifting by Modifying the Determinants of Breast Cancer Stage at Diagnosis: A Simulation Study." Cancers 16, no. 6 (2024): 1201. http://dx.doi.org/10.3390/cancers16061201.

Full text

Abstract:

Background: Breast cancer is the most common cancer in Canadian women; nearly 25% of women diagnosed with cancer have breast cancer. The early detection of breast cancer is a major challenge because tumours often grow without causing symptom. The diagnosis of breast cancer at an early stage (stages I and II) improves survival outcomes because treatments are more effective and better tolerated. To better inform the prevention of and screening for breast cancer, simulations using modifiable rather than non-modifiable risk factors may be helpful in shifting the stage at diagnosis downward. Method

APA, Harvard, Vancouver, ISO, and other styles

33

Abdualjabar, Rana Dhia’a, and Osama A. Awad. "Parallel extreme gradient boosting classifier for lung cancer detection." Indonesian Journal of Electrical Engineering and Computer Science 24, no. 3 (2021): 1610. http://dx.doi.org/10.11591/ijeecs.v24.i3.pp1610-1617.

Full text

Abstract:

Most lung cancers do not cause symptoms until the disease is in its later stage. That led the lung cancer having a high fatality rate compared to other cancer types. Many scientists try to use artificial intelligence algorithms to produce accurate lung cancer detection. This paper used extreme gradient boosting (XGBoost) models as a base model for its effectiveness. It enhanced lung cancer detection performance by suggesting three stages model; feature stage, XGBooste parallel stage and selection stage. This study used two types of gene expression datasets; RNA-sequence and microarray profiles

APA, Harvard, Vancouver, ISO, and other styles

34

Abdu-Aljabar, Rana Dhiaa, and Osama A. Awad. "Parallel extreme gradient boosting classifier for lung cancer detection." Indonesian Journal of Electrical Engineering and Computer Science 24, no. 3 (2021): 1610–17. https://doi.org/10.11591/ijeecs.v24.i3.pp1610-1617.

Full text

Abstract:

Most lung cancers do not cause symptoms until the disease is in its later stage. That led the lung cancer having a high fatality rate compared to other cancer types. Many scientists try to use artificial intelligence algorithms to produce accurate lung cancer detection. This paper used extreme gradient boosting (XGBoost) models as a base model for its effectiveness. It enhanced lung cancer detection performance by suggesting three stages model; feature stage, XGBooste parallel stage and selection stage. This study used two types of gene expression datasets; RNA-sequence and microarray profiles

APA, Harvard, Vancouver, ISO, and other styles

35

Oxnard, Geoffrey R., Eric A. Klein, Michael Seiden, et al. "Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)." Journal of Global Oncology 5, suppl (2019): 44. http://dx.doi.org/10.1200/jgo.2019.5.suppl.44.

Full text

Abstract:

44 Background: A noninvasive cfDNA blood test detecting multiple cancers at earlier stages could decrease cancer mortality. In earlier discovery work, whole-genome bisulfite sequencing outperformed whole-genome and targeted sequencing approaches for multi-cancer detection across stages at high specificity. Here, multi-cancer detection and TOO localization using bisulfite sequencing of plasma cfDNA to identify methylomic signatures was evaluated in preparation for clinical validation, utility, and implementation studies. Methods: 2301 analyzable participants (1422 cancer [ > 20 tumor types,

APA, Harvard, Vancouver, ISO, and other styles

36

Fry, Anna, Becky White, Diana Nagarwalla, Jon Shelton, and Ruth H. Jack. "Relationship between ethnicity and stage at diagnosis in England: a national analysis of six cancer sites." BMJ Open 13, no. 1 (2023): e062079. http://dx.doi.org/10.1136/bmjopen-2022-062079.

Full text

Abstract:

ObjectivesCancer stage at diagnosis is a determinant of treatment options and survival. Previous research has shown differences in barriers to presentation with cancer between ethnic groups. The completeness and quality of cancer stage and ethnicity data has improved markedly over recent years in England, allowing for comparison of stage distributions at diagnosis between ethnic groups. This study aimed to assess relationships between ethnic group and two outcomes: unknown stage cancer and late stage (stages 3 and 4) cancer, after adjustment for confounders.Design and settingA retrospective se

APA, Harvard, Vancouver, ISO, and other styles

37

Journal, Baghdad Science. "Determination of Serum CA125 and evaluate its efficiency as screening tool For Early Detection of Ovarian Tumors." Baghdad Science Journal 12, no. 1 (2015): 55–62. http://dx.doi.org/10.21123/bsj.12.1.55-62.

Full text

Abstract:

Epithelial ovarian cancer is the leading cause of cancer deaths in women. To date, an effective screening tool for ovarian cancer has not been identified Several clinical and biological factors including serum cancer antigen 125 (CA- 125) have been assessed for prognostic and predictive relevance CA-125 is an epithelial marker derived from coelomic epithelium. It is elevated in 90% of advanced ovarian cancers and in 50% of early ovarian cancers while 20% of ovarian cancers have low or no expression of CA- 125 CA-125 concentrations were measured by Mini Vidas test (VIDAS CA125 II / BIOMERIEUX /

APA, Harvard, Vancouver, ISO, and other styles

38

Habib, Khalid A., Maisaa G. Jumaa, and Munther J. Hussein. "Determination of Serum CA125 and evaluate its efficiency as screening tool For Early Detection of Ovarian Tumors." Baghdad Science Journal 12, no. 1 (2015): 55–62. http://dx.doi.org/10.21123/bsj.2015.12.1.55-62.

Full text

Abstract:

Epithelial ovarian cancer is the leading cause of cancer deaths in women. To date, an effective screening tool for ovarian cancer has not been identified Several clinical and biological factors including serum cancer antigen 125 (CA- 125) have been assessed for prognostic and predictive relevance CA-125 is an epithelial marker derived from coelomic epithelium. It is elevated in 90% of advanced ovarian cancers and in 50% of early ovarian cancers while 20% of ovarian cancers have low or no expression of CA- 125 CA-125 concentrations were measured by Mini Vidas test (VIDAS CA125 II / BIOMERIEUX /

APA, Harvard, Vancouver, ISO, and other styles

39

Rosendahl, Mikkel, Claus Kim Høgdall, and Berit Jul Mosgaard. "Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer." International Journal of Gynecologic Cancer 26, no. 4 (2016): 680–87. http://dx.doi.org/10.1097/igc.0000000000000675.

Full text

Abstract:

ObjectiveWith the 2013 International Federation of Gynecology and Obstetrics (FIGO) staging for ovarian, fallopian tube, and primary peritoneal cancer, the number of substages changed from 10 to 14. Any classification of a malignancy should easily assign patients to prognostic groups, refer patients to individualized treatments, and allow benchmarking and comparison of patients and results between centers. The stage should reflect survival in particular. The objective of the study was to validate these requirements of the revised FIGO staging on a high number of ovarian cancer patients.Materia

APA, Harvard, Vancouver, ISO, and other styles

40

Heller, Danielle R., Alexander S. Chiu, Kaitlin Farrell, Brigid K. Killelea, and Donald R. Lannin. "Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?" Cancers 11, no. 4 (2019): 500. http://dx.doi.org/10.3390/cancers11040500.

Full text

Abstract:

: Background: Despite screening mammography, the incidence of Stage IV breast cancer (BC) at diagnosis has not decreased over the past four decades. We previously found that many BCs are small due to favorable biology rather than early detection. This study compared the biology of Stage IV cancers with that of small cancers typically found by screening. Methods: Trends in the incidence of localized, regional, and distant female BC were compared using SEER*Stat. The National Cancer Database (NCDB) was then queried for invasive cancers from 2010 to 2015, and patient/disease variables were compar

APA, Harvard, Vancouver, ISO, and other styles

41

Marinac, Catherine, Elizabeth O'Donnell, Rita Shaknovich, et al. "Multi-cancer early detection (MCED) test performance in cancer survivors." Journal of Clinical Oncology 42, no. 16_suppl (2024): 1628. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1628.

Full text

Abstract:

1628 Background: Cancer survivors (CS) are at risk for recurrent or new primary tumors in any organ, but there is lack of clear guidance and options for long-term surveillance. We analyzed the performance of a blood-based MCED test that detects cancer-specific methylation patterns and predicts cancer signal origin (CSO) in CS in the PATHFINDER study (PF; NCT04241796). Methods: PF enrolled6662 participants (pts) ≥50 yr without clinical suspicion of cancer; 6578 samples were analyzed with a refined MCED test. Pts were stratified by CS status (treated cancer >3 yr prior to study vs no prior ca

APA, Harvard, Vancouver, ISO, and other styles

42

S. Nassir, Eman. "Detection of Serum Ferritin in Women with Breast Cancer." Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) 25, no. 1 (2017): 23–27. http://dx.doi.org/10.31351/vol25iss1pp23-27.

Full text

Abstract:

 Breast cancer is one of the most common cancers in females. In Iraq there are noticeable elevation in incidence rates and prevalence of advanced stages of breast cancer. Ferritin is intracellular iron storage protein abundant in circulation and its main application in differential diagnosis of anemia. The level of serum ferritin was found raised in various cancers including breast cancer. The aim of this study was to assess whether the serum ferritin concentration would be altered in Iraqi women with breast cancer and it could be related to progression of disease. Sixty eigh

APA, Harvard, Vancouver, ISO, and other styles

43

Bernstein, Ezra, Shiran Shapira, Shahar Lev-Ari, et al. "One-stop-shop for cancer screening: A model for the future." Journal of Clinical Oncology 39, no. 15_suppl (2021): 10554. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.10554.

Full text

Abstract:

10554 Background: Cancer is the second leading cause of death globally. Early detection will often greatly reduce mortality for many cancers, increase treatment effectiveness, and improve the quality of life for cancer patients, and, by implementing evidence-based prevention strategies, 30–50% of cancers can be prevented. Screening for different cancer types separately is inefficient. A solution is the Integrated Cancer Prevention Center (ICPC), a program with specialists in each discipline who test for multiple cancers during one visit. Methods: This is a prospective cohort study of 17,104 se

APA, Harvard, Vancouver, ISO, and other styles

44

Andaya, Amelito Manuel, A. Miguel Andaya, Stanley Atencah, Jason Holligan, and Chinenye Egwuonwu. "Abstract 4973: Assessing urban-rural differences in the outcomes of the most common cancers in Georgia: Incidence rates and stage at diagnosis." Cancer Research 85, no. 8_Supplement_1 (2025): 4973. https://doi.org/10.1158/1538-7445.am2025-4973.

Full text

Abstract:

Introduction: Lung, pancreatic, colon, prostate and breast cancers are the leading causes of cancer-related deaths in Georgia. Mortality is highest in rural counties which have higher poverty rates and larger composition of minority population. Our study aims to compare the proportion of the five most common cancers in Georgia that were diagnosed at late stages between urban and rural county locations. Methods: The National Institutes of Health State Cancer Profiles database was examined for incidence rates of breast, colon, lung, prostate and pancreatic cancers from 2017 to 2021 in Georgia. A

APA, Harvard, Vancouver, ISO, and other styles

45

Clèries, Ramon, Alberto Ameijide, Maria Buxó, et al. "Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain." International Journal of Environmental Research and Public Health 20, no. 1 (2022): 405. http://dx.doi.org/10.3390/ijerph20010405.

Full text

Abstract:

Mortality from cardiovascular disease (CVD), second tumours, and other causes is of clinical interest in the long-term follow-up of breast cancer (BC) patients. Using a cohort of BC patients (N = 6758) from the cancer registries of Girona and Tarragona (north-eastern Spain), we studied the 10-year probabilities of death due to BC, other cancers, and CVD according to stage at diagnosis and hormone receptor (HR) status. Among the non-BC causes of death (N = 720), CVD (N = 218) surpassed other cancers (N = 196). The BC cohort presented a significantly higher risk of death due to endometrial and o

APA, Harvard, Vancouver, ISO, and other styles

46

Pruitt, Margaret, Rajesh Naidu Janapala, and Faysal Haroun. "Patterns of lung cancer in people living with human immunodeficiency virus (HIV): A retrospective, single-center study in Washington, D.C." Journal of Clinical Oncology 39, no. 15_suppl (2021): e21154-e21154. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21154.

Full text

Abstract:

e21154 Background: Lung cancer is the leading cause of cancer death and the most common non-acquired immune deficiency syndrome defining malignancy in people living with HIV (PLWH). Disparities in outcomes have been observed despite lung cancer mortality reportedly decreasing in the general population over the last decade due to lower rates of smoking and the advent of novel therapies. To better understand the current trend in lung cancer in PLWH, we explored demographic characteristics, comorbidities, and lung cancer pathology and molecular data in this population. Methods: A retrospective se

APA, Harvard, Vancouver, ISO, and other styles

47

Doshi, Apoorva, Grant Richard Williams, and Smith Giri. "Racial disparities in cancer stage at diagnosis among older adults with gastrointestinal cancers in the southeastern United States." Journal of Clinical Oncology 43, no. 4_suppl (2025): 806. https://doi.org/10.1200/jco.2025.43.4_suppl.806.

Full text

Abstract:

806 Background: Prior studies have documented racial disparities in survival among older adults with various gastrointestinal (GI) cancers, but mechanisms remain poorly understood. We hypothesized that delayed diagnosis leading to advanced cancer stage at presentation could be a contributing factor to these disparities. Methods: We included adults ≥ 60 years with newly diagnosed GI cancers presenting for initial consultation at University of Alabama at Birmingham from October 2017 to April 2024. Using self-reported race and ethnicity, we stratified patients into Non-Hispanic Whites, Non-Hispan

APA, Harvard, Vancouver, ISO, and other styles

48

Ris, Frederic, Minia Hellan, Jonathan Douissard, et al. "Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results." Cancers 13, no. 16 (2021): 4104. http://dx.doi.org/10.3390/cancers13164104.

Full text

Abstract:

This is an early clinical analysis of the DEEPGENTM platform for cancer detection. Newly diagnosed cancer patients and individuals with no known malignancy were included in a prospective open-label case-controlled study (NCT03517332). Plasma cfDNA that was extracted from peripheral blood was sequenced and data were processed using machine-learning algorithms to derive cancer prediction scores. A total of 260 cancer patients and 415 controls were included in the study. Overall, sensitivity for all cancers was 57% (95% CI: 52, 64) at 95% specificity, and 43% (95% CI: 37, 49) at 99% specificity.

APA, Harvard, Vancouver, ISO, and other styles

49

Rousseau, Benoît, Benoist Chibaudel, Jean-Baptiste Bachet, et al. "Stage II and Stage III Colon Cancer." Cancer Journal 16, no. 3 (2010): 202–9. http://dx.doi.org/10.1097/ppo.0b013e3181ddc5bf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Yusof, Hazwani Mohd, Sharaniza Ab-Rahim, Wan Zurinah Wan Ngah, Sheila Nathan, A. Rahman A Jamal, and Musalmah Mazlan. "Metabolomic characterization of colorectal cancer cell lines highlighting stage-specific alterations during cancer progression." BioImpacts 11, no. 2 (2020): 147–56. http://dx.doi.org/10.34172/bi.2021.22.

Full text

Abstract:

Introduction: Metabolomic studies on various colorectal cancer (CRC) cell lines have improved our understanding of the biochemical events underlying the disease. However, the metabolic profile dynamics associated with different stages of CRC progression is still lacking. Such information can provide further insights into the pathophysiology and progression of the disease that will prove useful in identifying specific targets for drug designing and therapeutics. Thus, our study aims to characterize the metabolite profiles in the established cell lines corresponding to different stages of CRC. M

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!